The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.
 
Nienke A De Glas
No Relationships to Disclose
 
Esther Bastiaannet
No Relationships to Disclose
 
Frederiek van den Bos
No Relationships to Disclose
 
Simon Mooijaart
No Relationships to Disclose
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Karijn Suijkerbuijk
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Speakers' Bureau - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD (Inst); Roche (Inst)
 
Maureen J.B. Aarts
Research Funding - Pfizer (Inst)
 
Franchette van den Berkmortel
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Marye Boers-Sonderen
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre
 
Alfonsus Johannes Maria van den Eertwegh
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - BMS; Roche; Sanofi
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche; Sanofi
 
Jan Willem de Groot
Employment - Bristol-Myers Squibb; MSD
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Seerave Foundation (Inst)
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AIMM Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Djura Piersma
No Relationships to Disclose
 
Rozemarijn Van Rijn
No Relationships to Disclose
 
A. J. Ten Tije
No Relationships to Disclose
 
Michel W.J.M. Wouters
No Relationships to Disclose
 
Johanna Elisabeth A. Portielje
No Relationships to Disclose
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre
Research Funding - Bristol-Myers Squibb